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Abstract: Over the last decade, there has been an increasing interest among researchers for human mesenchymal 
stromal cells (MSC). Their regenerative properties, multilineage differentiation capacity and immunomodulatory prop-
erties make them promising candidates for treatment in various conditions. Emerging biotechnology companies specia-
lized in cellular and regenerative therapies have been focusing their interest on MSC-based therapies, and their use in 
clinical trials has steadily increased. Notably, MSC are currently tested in clinical trials addressing unmet medical needs 
in the field of bone fracture repair and more specifically in non-union and delayed union fractures where the bone repair 
process is impaired. Although MSC can be isolated from various tissues, the most commonly studied sources are bone 
marrow (BM) and adipose tissue (Ad). In this article, we reviewed the literature directly comparing BM- and Ad-MSC 
for their in vitro characteristics and in vivo osteogenic potential to determine which source of MSC would be more ap-
propriate for bone fracture repair. As considerable variations in experimental settings between studies were found, our 
review was based on studies meeting specific sets of criteria, notably regarding donors’ age and gender. This review of 
side-by-side comparisons suggests that while BM-and Ad-MSC share common general characteristics, BM-MSC have a 
higher intrinsic osteogenic capacity in vitro and bone repair potential in vivo. 
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1. Introduction 
egenerative medicine is a promising emerging 
therapeutic field, notably for bone repair. With 
their unique biological properties, human me-
senchymal stromal cells (MSC) may be particularly 
interesting for this field. MSC are non-hematopoietic  
multipotent stromal cells that were first isolated and 
characterized from bone marrow (BM) in 1968 by 
Friedenstein et al.[1]. Using their plastic adherence 
property, the authors were able to isolate fibrob-
last-like clonogenic cells that they called colony for-
ming unit-fibroblasts (CFU-F)[1,2]. These cells have 
been shown to exhibit a strong replication capacity in  
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vitro and to differentiate into different cell lineages 
including osteoblasts, chondrocytes and adipocytes[3–5]. 
In addition to this tri-lineage differentiation capacity, 
MSC may also be able to give rise to other mesoder-
mal lineage cells such as skeletal muscle and tendon 
cells[6–11]. Since then, MSC have been isolated from other 
sources (adipose tissue, synovial membrane, placental 
tissues, umbilical cord blood, blood, dental pulp, dermal 
tissue or trabecular bone) than bone marrow[10, 12–18]. 
Recently, the heterogeneity in isolation procedures 
and culture protocols prompted the Cell Committee of 
the International Society for Cellular Therapy (ISCT) 
to harmonize the definition of MSC[19]. MSC were 
defined according to the following 3 minimum criteria: 
(i) MSC must be purified based on their plastic ad-
herence when maintained in standard culture condi-
tions; 
(ii) MSC must express the mesenchymal markers 
CD105, CD73 and CD90 and must not express the 
hematopoietic markers CD45, CD34, CD14 or CD11b, 
CD79α or CD19 and HLA-DR;  
(iii) MSC must be able to differentiate in appropri-
ate in vitro conditions into osteoblasts, adipocytes and 
chondrocytes.  
MSC from bone marrow were the first to be investi-
gated twenty years ago in a clinical trial by Lazarus et al., 
in patients with non-Hodgkin's lymphoma[20]. Since 
then, the number of clinical trials using MSC has in-
creased steadily. To date, according to data reported 
by the US National Institutes of Health[21], more than 
500 clinical trials using human MSC are either com-
pleted or ongoing. In these clinical trials, autologous 
or allogeneic MSC are used for the treatment of vari-
ous diseases, including haematological diseases, autoi-
mmune diseases, liver, kidney and lung diseases, neu-
rological diseases and cartilage and bone diseases (e.g., 
osteonecrosis, spinal fusion, delayed and non-union 
fractures). 
2. Rationale of Cell Therapy for Fracture Repair 
Bone being naturally regenerative, fractures are cur-
rently well-managed in the majority of patients. How-
ever, there are traumatic situations in which bone fails 
to regenerate itself leading to non-union[22]. While 
there is no universally accepted definition, non-union 
refers to a fracture that has not united within 6 to 9 
months after fracture onset and that requires additional 
surgical or non-surgical intervention. An overall rate of 
5 to 10% non-union is reported in the literature[3]. 
Standard treatment options (i.e., bone auto- or allo-
graft) typically involve highly invasive surgeries, 
which have a significant morbidity associated to con-
siderable risk of complications (in 20 % of patients), 
such as infections, and may require months of rehabil-
itation[24,25]. Although the exact aetiology remains unk-
nown, the impaired bone repair capacity in non-union 
fractures was reported to be associated with excessive 
mechanical instability of the fracture, reduced bone 
vascularity, reduced number of progenitor cells (at 
fracture site as well as in iliac crest bone marrow), 
along with a decreased proliferation capacity of said 
progenitors[26–28]. Therefore, cell-based therapy, by 
providing additional functional MSC, could offer an 
appealing therapeutic alternative to treat bone frac-
tures. 
BM-MSC have historically been the most widely 
investigated in clinical trials[29–31]. But supported by 
interesting preclinical results, the number of clinical 
trials involving Ad-MSC has significantly increased 
over the past years[29,32,33]. In the US National Insti-
tutes of Health database[21], 11 delayed and non-union 
fracture repair trials using BM-MSC or Ad-MSC are 
reported, among which 9 with BM-MSC and 2 with 
Ad-MSC for non-union applications (Table 1). These 
trials are all either “starting” or “recruiting” and one 
can expect the results to be available in the near future. 
Preclinical studies have been and are still being 
conducted to understand the characteristics of BM- 
and Ad-MSC and to assess their regenerative potential 
in bone repair models. Notably, a growing number of 
preclinical studies have been undertaken to directly 
compare the two types of MSC with the aim to deter-
mine their commonalities and specificities. However, 
the heterogeneity in experimental settings used by 
different teams makes the comparison between studies 
difficult and conclusions hard to draw. This article 
aims to provide a critical review of the preclinical stu-
dies investigating in vitro and in vivo the characteris-
tics and the bone formation potential of BM- and 
Ad-MSC. 
3. Methodology 
Only a few specific studies which directly compared 
human BM-MSC and Ad-MSC were selected for this 
review. The analysis of this literature underlines con-
siderable variations between results obtained from 
different research teams that may be linked to the he-
terogeneity in (i) donors and donors’ characteristics 
(e.g., health status, gender, age), (ii) in vitro/ex vivo 
protocols (e.g., sample isolation sites and methods,  
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Table 1. List of clinical trials using BM-MSC and Ad-MSC in delayed and non-union fractures 
Study Title Status Identifier Phase Product Cell source Sponsor 
BM-MSC       
Treatment of Atrophic Non-union Frac-
tures by Autologous Mesenchymal Stem 
Cell Percutaneous Grafting 
Not yet  
Recruiting 
(Nov 2017) 
NCT01429012 II BM-MSC Autologous University Hospital of 
Liege 
Phase 2b/3 Study on Autologous Osteob-
lastic Cells Implantation in Hypotrophic 
Non-Union Fractures 
Recruiting 
(Jun 2017) 
NCT01756326 II/III Differentiated BM-MSC 
(PREOB®) 
Autologous Bone Therapeutics S.A, 
Belgium 
Phase 1/2a Study on Allogeneic Osteob-
lastic Cells Implantation in Delayed-Un-
ion Fractures 
Recruiting  
(Jul 2016) 
NCT02020590 I/II Differentiated BM-MSC 
(ALLOB®) 
Allogeneic Bone Therapeutics S.A, 
Belgium 
Autologous BM-MSC Transplantation in 
Combination With Platelet Lysate (PL) for 
Nonunion Treatment 
Recruiting 
(Aug 2017) 
NCT02448849 II/III BM-MSC + Platelet Ly-
sate  
Autologous Royan Institute, Iran 
Mesenchymal Stem Cells; Donor and Role 
in Management and Reconstruction of 
Nonunion Fracture 
Recruiting  
(Jan 2016) 
NCT01626625 I BM-MSC + HA - Indonesia University, 
Indonesia 
Mesenchymal Stromal Cells for the Treat-
ment of Non-union Fractures of Long 
Bones 
Recruiting 
(Dec 2017) 
NCT02230514 I/II BM-MSC (XCEL-MT- 
OSTEO-ALPHA) + all-
ograft 
Autologous Banc de Sang i Teixits 
+ Hospital ASEPEYO 
Sant Cugat, Spain 
Mononucleotide Autologous Stem Cells 
and Demineralized Bone Matrix in the 
Treatment of Nonunion/Delayed Fractures        
Not yet  
recruiting 
NCT01435434 - BM-MSC + DBM (Ign-
ite®) 
Autologous Hadassah Medical Or-
ganization 
Evaluation of Efficacy and Safety of 
Autologous MSCs Combined to Biomate-
rials to Enhance Bone Healing 
Active, not 
Recruiting 
(Nov 2015) 
NCT01842477 I/II BM-MSC + BCP gra-
nules 
Autologous Institut National de la 
Santé Et de la Rech-
erche Médicale, France 
- REBORNE project 
Evaluation the Treatment of Nonunion of 
Long Bone Fracture of Lower Extremities 
Using Mononuclear Stem Cells From the 
Iliac Wing Within a 3D Tissue Engineered 
Scaffold 
Unknown 
(last update 
Nov 2013) 
NCT01958502 II BM-MSC (not expanded) 
+ collagen matrix 
Autologous Emdadi Kamyab Hos-
pital, Iran 
Ad-MSC       
A Clinical Trial to Assess the Effect of 
HC-SVT-1001 in the Surgical Treatment 
of Atrophic Pseudarthrosis of Long Bones 
(BONECURE) 
Recruiting 
(Apr 2017) 
NCT02483364 II Ad-MSC (HC-SVT-1001) 
+ TCP matrix 
Autologous Laboratorios Salvat, 
Spain 
Allogenic Mesenchymal Stem Cell for 
Bone Defect or Nonunion Fracture (AMSC) 
Recruiting NCT02307435 0 BM/Ad/UC-MSC (3 tr-
eatment groups) 
Autologous Indonesia University 
 
culture conditions) and (iii) readouts, outcomes and 
methods of analysis. In addition other undefined fac-
tors can also influence MSC properties. 
From 54 studies which directly compared 
BM-MSC and Ad-MSC, only a few studies that com-
pared BM-MSC and Ad-MSC from donors matched 
for age and/or gender were retained for analysis. 
Eighteen studies reporting data about yield and proli-
feration, immunophenotype, differentiation potential 
and/or bone formation/repair potential in vivo were 
considered. Five studies compared BM-MSC and 
Ad-MSC isolated from the same donors[33–38], which 
represents the most robust comparison as they are not 
biased by inter-individual variabilities, in particular 
age, gender and health status. Nine studies comparing 
age-matched donors were also retained, which include 
1 study on female donors only[39], 1 study on 50% 
male and 50% female donors[40], 2 studies on a close 
but not identical number of females and males[41,42], 
and 5 studies on donors matched for age but without 
specifying the gender[43–47]. Finally, 4 studies com-
pared the two types of MSC isolated from healthy 
donors, but with unknown age and gender[48–51].  
For bone formation/repair potential, there were li-
mited in vivo studies which compared both types of 
MSC. Therefore, 2 studies comparing BM-MSC and 
Ad-MSC with unknown health condition, age and 
gender of donors[52,53] and 5 studies using the two 
types of MSC isolated from other species[54–58] were 
considered for this review. 
Sabrina Ena, Julia Ino, Aurelie Neirinck, et al. 
 
 Journal of Medicines Development Sciences (2015)–Volume 1, Issue 2 15 
4. Comparison of BM-MSC and Ad-MSC 
Characteristics  
It is noteworthy to mention that BM-MSC and Ad- 
MSC share the general minimum criteria defined by 
Dominici et al. in 2006[19]. However, preclinical stu-
dies identified the differences regarding their yield, 
proliferation, phenotype and differentiation properties. 
This section aims to discuss the commonalities and dif-
ferences reported for BM-MSC and Ad-MSC (Table 
2), with the focus on studies which involves direct 
comparison between the BM-MSC and Ad-MSC iso-
lated from donors sharing similar characteristics as 
described above. 
4.1 Collection, Isolation, Yield and Proliferation 
The use of MSC for clinical applications requires a 
large number of cells, and although MSC can be ex-
tensively expanded in vitro, this expansion is not inde-
finite due to replicative senescence[59,60]. With the 
availability of different MSC sources, comparative 
studies have been conducted to determine whether, 
and to what extent, the source affects in vitro the ex-
pansion capacity and yield of MSC. 
BM-MSC are isolated from bone marrow aspirates 
usually from the iliac crests. Alternative harvesting 
sites are femoral heads (from total hip arthroplasty of 
an elderly patient population), sternum and less fre-
quently vertebrae. The commonly applied preparation 
method for the generation of BM-MSC is density gra-
dient centrifugation, but other methods rely on their 
properties to adhere to plastic[1,61–66]. 
Ad-MSC are isolated from lipoaspirates obtained 
during liposuction, lipoplasty or lipectomy procedures. 
The commonly applied preparation method implies 
enzymatic digestion with collagenase followed by 
centrifugation, washing and plating onto plastic sur-
faces[67]. Ad-MSC can be isolated from any types of 
white adipose tissue, including subcutaneous and 
omental fat[61,63,67–70].  
While the MSC isolation rate from Ad and BM 
sources is comparable, the yield and expansion capac-
ity are reported higher for Ad than for BM prepara-
tions[6,63,71–73]. Indeed, across literature (without taking 
into account donors’ characteristics), studies and re-
views generally report that Ad-MSC have a higher 
expansion capacity than BM-MSC both in terms of 
proliferation rate and cell doubling number[31,61,63]. In 
addition, Ad-MSC would have longer proliferation 
capacity through cell culture passages and a lower 
senescence rate compared to BM-MSC[31,61,63]. 
The analysis of selected comparative studies (10) 
reporting proliferation and yield data gives a con-
trasted picture with 5 studies favouring Ad-MSC, 3 
favouring BM-MSC and 2 supporting equivalence.  
Zhu et al.[41] and Bochev et al.[33] showed that 
Ad-MSC reach confluence faster than BM-MSC (but 
with marked differences between studies: 6 vs 9 days 
(to reach ~8 × 104 cells from an initial seeding of 5 × 
103 cells/well) and 15 vs 20–22 days). Zhu et al.[41] 
and Chen et al.[37] found that Ad-MSC have a shorter 
doubling time (28 hours vs 39 hours[41]).  
Further, Chen et al.[37] showed that with young do-
nors (36.4 ± 11.8 years old), 5/8 BM-MSC cultures 
reached passage 9 and with elderly donors (71.4 ± 3.6 
years old), 2/4 BM-MSC cultures reached passage 
7[37]. On the contrary, the aging effect for Ad-MSC 
was not significant up to passage 9 for both the young 
and elderly donor groups. Ad-MSC achieved a cumu-
lated cell number of 108 within 4 passages and 1013 
within 7 passages whatever the donors’ age (young or 
elderly groups), while BM-MSC from both age groups 
reached a cumulated cell number of 108 after 5 pas-
sages but only BM-MSC from young adult donors 
reached 1013 at passage 8; the cumulated cell number 
of BM-MSC from the elderly group did not go over 
109[37]. These results suggest that contrarily to Ad- 
MSC, BM-MSC proliferation capacity decreases with 
passage numbers and age. Dmitrieva et al.[38] observed 
a similar proliferation rate between both types of MSC 
at early passages: the population doubling time was 
about 1–1.5 day for both types of MSC. However 
BM-MSC population doubling time increased by pas-
sage 3 (by ~5 fold) and CFU-F frequency declined by 
passage 4 (by ~4 fold) while population doubling time 
and CFU-F were maintained through passages in 
Ad-MSC cultures. Also, signs of senescence appeared 
earlier in BM-MSC cultures than in Ad-MSC (passage 
4 vs 6)[38]. Najar et al.[48] showed that after the primo-
culture, Ad-MSC yield a 6 fold higher CFU-F number 
compared to BM-MSC (number of CFU-F obtained 
from 106 cells initially seeded: 5080 ± 553 for Ad-MSC 
vs. 852 ± 135 for BM-MSC).  
In contrast, Vishnubalaji et al.[44] obtained a higher 
number of CFU-F for BM-MSC than for Ad-MSC at 
passage 1 (25.9 ± 2.9 vs. 17.9 ± 2.8), but CFU-F fre-
quency of BM-MSC decreased with passage numbers 
while it was maintained in Ad-MSC cultures (CFU-F 
number: 8.5 ± 3.8 vs. 24.2 ± 2.8 at passage 4). Jin et 
al.[46] found that 2.5 times more CFU-F were formed 
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from BM-MSC than from Ad-MSC (16.5 ± 4.4 vs. 6.4 ± 
1.6 at passage 3) and population doubling of BM-MSC 
was higher than that of Ad-MSC (by ~3 fold at pas-
sage 2 and ~2 fold at passage 3), although cell growth 
of both BM-MSC and Ad-MSC arrests at passages 
11–12. In addition, one study reports that the expansion 
potential of BM-MSC was retained at later passages 
than that of Ad-MSC (passage 10 vs passage 7)[36]. 
Finally, 2 studies[34,40] did not show differences in 
yield, proliferation or senescence between BM-MSC 
and Ad-MSC.   
In summary, a review of data from comparative 
studies does not give consistent results about the yield 
and proliferation capacity of BM-MSC and Ad-MSC 
and definitive conclusions seem difficult to draw. 
Further, the lack of quantitative data (e.g., size of CFU, 
absolute cell count seeded or collected…) makes de-
tailed analyses difficult. Although BM and Ad tissue 
donors’ characteristics were similar within studies, 
they were different from one study to another. Also, 
besides donors’ characteristics, MSC clonogenic abil-
ity and proliferation rate can also depend on the har-
vesting site and culture conditions, which could ex-
plain the different outcomes obtained between studies. 
The development of standardized procedures, proto-
cols and methods is therefore necessary to ensure re-
liable and comparable results between studies and 
research teams. 
4.2 Cell Morphology and Identity 
All the studies which focused on MSC morphology 
(whatever the donors’ characteristics) agreed that there 
are no or few observable differences between BM-MSC 
and Ad-MSC as both exhibit a similar fibroblast-like, 
elongated spindle shape, morphology[33,47,61,74,75].  
When analysing the immunophenotypic data repor-
ted by comparative studies (15), only a few subtle dif-
ferences in surface marker expression between BM- 
MSC and Ad-MSC could be identified (48 markers rep-
orted in total, either tested extensively such as CD73 
or CD45 or occasionally like CD49c or CD133)[33,35–48] 
(Table 3). 
BM-MSC and Ad-MSC both express the stromal 
surface markers CD13, CD73, CD90, CD105 and 
CD166, and STRO-1 to a lesser extent. Both do not 
express the hematopoietic and immune markers CD3, 
CD4, CD11a,b,c, CD14, CD16, CD19, CD24, CD33, 
CD34, CD38, CD45, CD56, CD58, CD62b, CD79a 
and HLA-DR nor the endothelial/platelet markers 
CD31, CD36, CD133 or CD117. They have both been 
also shown to express the integrin CD29 (β-integrin) 
and CD44 (hyaluronan receptor). 
Our review has identified only a few markers that 
are differentially expressed between BM-MSC and 
Ad-MSC: these markers however have not been the 
most extensively studied. CD49d (integrin α4) is re-
ported to be expressed by Ad-MSC (although incons-
tantly) but not or only weakly by BM-MSC, whereas 
CD106 (vascular cell adhesion protein 1) and PODXL 
(podocalyxin-like protein 1) are moderately to strong-
ly expressed by BM-MSC but not expressed by 
Ad-MSC[35,36,39,41].  
Through extensive literature review, it is found that 
most of the studies agree that both types of MSC have 
similar profiles of surface antigen expression[7,31,62,68]. 
Several studies have reported that Ad-MSC express 
the hematopoietic progenitor cell antigen CD34 im-
mediately after isolation and during the first stages of 
cell culture[31,76–80] while it is not expressed by BM- 
MSC[31,62,80,81]. However, no difference in CD34 ex-
pression is reported in side-by-side comparisons be-
tween BM-MSC and Ad-MSC (Table 3). These diver-
gences may be explained by variations in used proto-
cols (e.g., different culture media, culture duration, 
proliferation stage, passage number, donors’ characte-
ristics, antibody sources). 
4.3 BM-MSC and Ad-MSC Gene Signature 
Understanding at the molecular level the pathways 
that distinguish BM-MSC from Ad-MSC in their dif-
ferentiation toward the osteoblastic lineage may help 
designing cell therapies for bone repair. Based on 
mRNA analysis such as qRT-PCR, microarray or 
RNAseq, studies evidenced differences between BM- 
and Ad-MSC that are implicated in various signalling 
pathways. This could suggest functional differences 
between both MSC types.  
According to the selection criteria of this review 
(i.e., age and gender matching donors), 6 articles have 
been selected[39,42–44,47,81]. From these 6 publications 
however, 2 were discarded because the number of cell 
passages was either too large or not clearly specified[43] 
(using P2 to P6 cells without additional clarification), 
which can cause artefactual background, or because 
the comparison was not performed with non-induced 
BM-MSC and Ad-MSC (comparing only differen-
tiated cells)[44]. Therefore, only 4 papers were kept for 
this review. In these articles, BM- and Ad-MSC were 
expanded with a known and limited number of pas-
sages (P1 to P3), were grown in minimal conditions 
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without induction towards lineage and were directly 
compared[39,42,47,81]. 
In Brocher et al.[42], the expression of genes of the 
osteogenic, angiogenic and adipogenic pathways from 
BM-MSC and Ad-MSC was compared. The compari-
son of expression level of BMP2 and BMP4 coding 
for 2 osteogenic growth factors showed that BM-MSC 
expressed significantly higher mRNA levels of these 
factors compared to Ad-MSC (fold change between 
BM-MSC and Ad-MSC was 5 for BMP2 and 3 for 
BMP4).  The same was observed for mRNA coding 
for the pro-angiogenic molecules VEGF and ANGPT1 
with a fold increase of 2 and 5, respectively[42]. VEGF 
is notably known to stimulate bone formation by in-
creasing angiogenesis, to maintain MSC survival and 
to promote osteoblast differentiation. Finally, genes 
involved in adipogenesis, such as those coding for the 
visfatin and adiponectin proteins, were downregulated 
in BM- compared to Ad-MSC. Similarly, Noël et al.[81] 
showed by microarray from Passage 1 (P1) BM-MSC 
and Ad-MSC that genes involved in chondro/osteo-
genesis, such as HES1, DLX5, TWIST1, BGLAP, OSX, 
SOX9, WNT5A, TGFΒ1 and VEGF were upregulated 
in BM-MSC. These results were confirmed recently in 
Reinisch et al.[47], which showed that genes related to 
chondro/osteogenesis such as RUNX2, RUNX3, BGLAP, 
MMP13, ITGA10, DLX5, DLX6, SPP1, BGLAP, ALPL, 
SPP1, COL2A, COL10A, and ACAN were upregulated 
in BM-MSC compared to Ad-MSC. The same resear-
chers also confirmed that hemato/angiogenic genes such 
as INHBA, FZD1, TLR4, DGFC, ANGPT1, VEGFA, 
CTGF, and VEGFC were also upregulated in BM- 
MSC, confirming Brocher’s results[42,47]. 
The same trend was shown for BGLAP, SPARC and 
RANKL by Pachón-Peña et al.[39]. Finally, as in Bro-
cher et al., adipogenesis-related mRNA levels in non- 
induced Ad-MSC largely exceeded (although without 
reaching statistical significance) those of BM-MSC, 
for PPARG  (0.83 ± 1.73 vs. 0.03 ± 0.09), CEBPA 
(0.02 ± 0.02 vs. 0.01 ± 0) and FABP4 (1.75 ± 4.09 vs. 
0.02 ± 0.02)[39].  
Altogether, these 4 studies evidence that the ex-
pression of genes which are related to the chon-
dro/osteogenic and angiogenic pathways are largely 
more expressed in BM-MSC compared to Ad-MSC. 
Whereas, an opposite observation for the adipogenic 
pathway suggests that both MSC exhibit a gene sig-
nature related to their source (Table 2).  
4.4 In Vitro Multilineages Differentiation Potential  
In vitro analysis of MSC differentiation potential un-
der appropriate culture conditions revealed that BM- 
MSC and Ad-MSC displayed the capacity of differen-
tiation into the adipogenic, chondrogenic and osteo-
genic lineages. Yet, the important question which rai-
sed in the context of bone tissue engineering is 
whether MSC from both sources have similar osteo-
genic potential. 
To answer this question, 14 articles were selected 
based on the selection criteria used for this review. 
From these 14 articles, 6 have investigated the trili-
neages differentiation potential[34,36,40,46,47,81], 5 the 
osteogenic and the adipogenic potential[33,38,39,43,44], 1 
the osteogenic and chondrogenic potential[45] and 2  
the osteogenic potential only[37,42]. 
MSC can be induced to differentiate along the three 
lineages using culture medium supplemented with 
different factors. For osteogenic differentiation the 
medium is generally supplemented with dexametha-
sone, β-glycerophosphate and ascorbic acid. This me-
dium induces osteoblastic differentiation that can the-
reafter be revealed using staining protocols for ALP 
activity, calcium deposition or matrix mineralization 
(e.g., Alizarin Red, Von Kossa and Giemsa staining) 
or by mRNA analysis measuring the expression levels 
of osteoblastic gene.  
Im et al.[45] showed that after 2 weeks of culture in 
osteogenic medium, 85% of BM-MSC were ALP pos-
itive against 28% for the Ad-MSC, reaching 92% and 
45% respectively after 3 weeks of culture. The num-
ber of mineralization nodules and the calcium content 
were also quantitatively higher in BM-MSC than in 
Ad-MSC[45]. Five other studies (using ALP activity, 
Von Kossa, Alizarin Red staining or qPCR) confirmed 
the conclusions made by Im et al.[45] that under osteo-
genic induction, BM-MSC display higher osteogenic 
capacity than Ad-MSC[33,36,37,44,81]. It was also shown 
after 3 weeks of osteogenic induction that the number 
of mineralizing colonies (number of Alizarin Red pos-
itive colonies vs the total number of colonies) was 
higher for BM-MSC (~43%) than for Ad-MSC 
(~22%)[36]. At early timepoint (10 days of induction) 
too, BM-MSC were shown to have significantly high-
er osteogenic potential than Ad-MSC (2 fold increase 
in fluorescence-based calcium level quantification, 
p=0.02)[44]. Further, three key bone genes, OSX, ALPL 
and BGLAP were shown to be more strongly up-reg-
ulated in differentiated BM-MSC than in differen-
tiated Ad-MSC[37,81]. 
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Seven studies found that BM- and Ad-MSC dis-
played the same osteogenic differentiation capacity 
after osteogenic induction[34,38,39,42,43,46,47]. Jin et al., 
Reinisch et al., and Wagner et al. showed that BM- and 
Ad-MSC can successfully differentiate into osteogenic 
lineage based on ALP[46,47] or Von Kossa staining[43]. 
The comparisons are however not quantitative and 
therefore difficult to be interpreted. Four studies 
showed that there is no significant quantitative differ-
ence between induced BM- and Ad-MSC by quantifi-
cation of ALP activity[34,42] or colonies positive for 
Alizarin Red staining[38,39].  
Finally, only one study suggests that after 3 weeks 
of osteogenic induction, Ad-MSC showed higher cal-
cium deposition compared to BM-MSC based on Ali-
zarin red staining, but this was not quantitatively as-
sessed[40].  
Among these 14 studies, 6 concluded on the supe-
riority of BM-MSC[33,36,37,44,45,81], 7 observed equiva-
lence[34,38,39,42,43,46,47] and a single one superiority of Ad- 
MSC[39]. Taking into account only studies (10 out of 
the 14) providing quantitative osteogenic assessments, 
the superiority of BM-MSC was demonstrated in 6 
studies[33,36,37,44,45,81] and the equivalence in 4[34,38,39,42].  
Similar trends were observed for the adipogenic 
and chondrogenic potentials. Indeed among the 11 
studies investigating the adipogenic capacity of BM- 
and Ad-MSC, 3 reported a higher potential for 
Ad-MSC[36,39,44] and 8 reported equiva-
lence[33,34,38,40,43,46,47,81]. Finally, among the 7 studies 
investigating the chondrogenic capacity of BM- and 
Ad-MSC, 4 reported a higher potential for BM- 
MSC[36,40,45,47], 1 a higher potential for Ad-MSC[35] 
and 2 equivalence[44,81]. 
Although the results are not completely consistent, 
comparative data tend to support a more pronounced 
osteogenic and chondrogenic potential of BM-MSC as 
compared to Ad-MSC (6 studies against 4 for osteo-
genic potential; 4 against 3 for chondrogenic potential) 
(Table 2). 
 
Table 2. General comparison of BM-MSC and Ad-MSC characteristics 
Characteristics BM-MSC Ad-MSC References 
In vitro proliferation 
capacity  
Limited Limited 
Greater in 5/10 selected studies 
[59–60] 
[33,36–38,40–42,44,46,48] 
 Greater in 3/10 selected studies  [33,36–38,40–42,44,46,48] 
 Equivalent in 2/10 selected studies [33,36–38,40–42,44,46,48] 
Cell morphology Fibroblast-like morphology Fibroblast-like morphology [33,61,74,75] 
Immunophenotype Express stromal surface markers  
Do not express most haematopoietic lineage and 
immune markers  
Do not express endothelial/platelet markers CD31, 
CD36, CD133 and CD117 
Express CD29 and CD44 
Do not express or weekly express CD49d 
Moderately to strongly express CD106 and PODXL  
Do not express CD34 
Express stromal surface markers  
Do not express most haematopoietic li-
neage and immune markers  
Do not express endothelial/platelet mark-
ers CD31, CD36, CD133 and CD117 
Express CD29 and CD44 
Express CD49d (but not constantly) 
Do not express CD106 and PODXL 
Do not express or express CD34 at early 
stages 
[7,31,33,35–46,48,63,68,7
6–78,80]  
See Table 3 for detailed 
comparison of the results 
from the selected studies 
Gene signature Chondro/osteogenic genes: BMP2, BMP4, 
OSX, BGLAP, ALPL, VEGF, HES1, DLX5, 
TWIST1, BGLAP, OSX, SOX9, WNT5A, TGFΒ1, 
DLX6, COL2A, COL10A and ACAN 
Upregulated 
 
hemato/angiogenic genes: INHBA, FZD1, 
TLR4, DGFC, ANGPT1, VEGFA, CTGF, and 
VEGFC upregulated 
Adipogenic genes, FABP4, NAMPT, 
ADIPOQ, PPARG, CEBPA upregulated 
[39, 42, 47, 81] 
Multilineage differentiation capacity 
Osteogenic potential  > 6/14 studies > 1/14 studies [33,34,36–40,42–47,81] 
 Equivalent in 7/14 selected studies  
Adipogenic potential 
  
>3/11 studies 
 
[33,34,36,38–40,43,44,46,
47,81] 
 Equivalent in 8/11 selected studies  
Chondrogenic potential >4/7 studies >1/7 studies [34, 36, 40, 45–47, 81] 
 Equivalent in 2/7 selected studies  
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Table 3. Immunophenotypic comparison of BM-MSC and 
Ad-MSC  
  BM-MSC Ad-MSC 
Hematopoietic and immune markers 
CD3 Lymphocyte –(3) –(3) 
CD4 Lymphocyte –(1) –(1) 
CD10 Hematopoietic progenitor –(2)+(1) –(1)+(2) 
CD11a Integrin α L-Leukocyte –(1) –(1) 
CD11b Integrin αM-Leukocyte/NK –(1) –(1) 
CD11c Integrin αX-Leukocyte –(1) –(1) 
CD14 Macrophage –(10) –(10) 
CD16 NK/macrophage –(1) –(1) 
CD19 Lymphocyte B –(5) –(5) 
CD24 B cells –(1) –(1) 
CD33 Monocyte –(1) –(1) 
CD34 Early hematopoietic –(13) –(12)+(1 low) 
CD38 Plasma/B Cell –(2) –(2) 
CD45 Hematopoietic –(13) –(13) 
CD56 NK/macrophage –(2) –(2) 
CD58 Leukocyte/macrophage +(1) +(1) 
CD59 Immune +(1) +(1) 
CD62b Adhesion-leukocyte –(1) –(1) 
CD79a B cells –(3) –(2)+(1) 
CD184 CXCR4 –(2) –(2) 
HLA-DR Immune –(8) –(8) 
HLA-ABC Immune +(4) +(4) 
Mesenchymal markers 
CD13 Mesenchymal/myeloid marker +(4) +(4) 
CD73 Mesenchymal +(12) +(12) 
CD90 Mesenchymal +(12) +(12) 
CD105 Mesenchymal +(12) +(12) 
CD166 Mesenchymal +(9) +(8/1 moderate) 
CD271 Mesenchymal –(2) –(2) 
STRO-1 Mesenchymal progenitor +(4) +(3/1 low) 
SSEA4 Mesenchymal –(1) –(1) 
Integrin, cadherin and adhesion markers 
CD29 Integrin β1 +(9) +(9) 
CD44 Hyaluronan receptor +(8) +(8) 
1. CD49d Integrin α4 –(2)+(1 low) –(1)+(2) 
CD49c Integrin α3 +(1) +(1) 
CD49f Integrin α6 +(2) +(2) 
CD54  ICAM1 +(3 low) +(2 low/high)–(1) 
CD104 Integrin β4 –(1) –(1) 
2. CD106   VCAM1 +(2/2 low) –(4) 
CD144 V cadherin - Endothelial –(1) –(1) 
CD146 M CAM +(4) +(2 low)–(2) 
Continued 
  BM-MSC Ad-MSC 
Platelet and endothelial markers 
CD31 Platelet/Endothelial –(7) –(7) 
CD36 Platelet/Endothelial –(2) –(1)+(1) 
CD117 Stem cell –(3) –(3) 
CD133 Endothelial –(1) –(1) 
FLK1 VEGF receptor –(1) –(1) 
VEGFR2 VEGF receptor –(1) –(1) 
Others     
CD147 Neurothelin +(1) +(1) 
PODXL Podocalyxin-like protein 1 +(1) –(1) 
The immunophenotype data reported by 15 studies directly com-
paring BM-MSC and Ad-MSC isolated from donors with similar cha-
racteristics were compared[33,35–48].  
NK: Natural Killer, -: absence of expression, +: expression, low: 
low expression, moderate: moderate expression, high: high expression. 
The number in brackets corresponds to the number of studies reporting 
the corresponding result. 
 
5. In Vivo Osteogenic Potential of BM-MSC 
and Ad-MSC 
In order to evaluate the osteogenic potential of BM- 
MSC and Ad-MSC in vivo, the same approach used 
for assessing the in vitro MSC characteristics was ap-
plied. The in vivo literature is however limited. From 
the 11 articles directly comparing BM-MSC and Ad- 
MSC in bone formation/bone repair model, only 2 
meet the criteria defined for this review[41,47]. From the 
others, 4 articles do not specify the BM and/or Ad 
donors’ characteristics[50–53] and 5 compared BM-MSC 
and Ad-MSC isolated from others species such as 
rats[54], rabbits[55], dogs[56], pigs[57] and sheep[58]. Our 
analysis was therefore based on the 6 articles using 
human BM-MSC and Ad-MSC and when relevant, 
confronted to the results obtained with other species.  
To address the in vivo osteogenic potential, two as-
pects will be discussed in this section. First, the ec-
topic bone formation capacity investigated in 5 out of 
the 11 selected articles[42,47,50,52,54], and second, the 
orthotopic bone formation capacity evaluated in 6 out 
of the 11 selected papers[51,53,55–58]. 
5.1 Ectopic Bone Formation Capacity of BM-MSC 
and Ad-MSC 
The direct comparison of ectopic bone formation ca-
pacity of BM-MSC and Ad-MSC has been studied in 
5 articles: 4 using human MSC (with 2 meeting the 
selection criteria for this review[42,47]) and 1 using rat 
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MSC. 
Ectopic bone formation commonly occurs with 
BM-MSC in presence of calcium phosphate ceramics 
such as β-tricalcium phosphate (β-TCP) and/or hy-
droxyapatite (HA) after subcutaneous implantation in 
immunocompromised mice[82–86]. This ectopic bone 
formation model is useful to assess the intrinsic ca-
pacity of cells to produce mineralized matrix outside a 
bone environment, even if this model is partly biased 
by the use of osteoconductive scaffolds.  
In an experiment comparing BM-MSC and Ad- 
MSC from 14 different donors (7 per source and mat-
ched for age), Brocher et al.[42] have shown that BM- 
MSC seeded on β-TCP scaffolds induced new bone 
deposition onto the scaffold (6/7 donors and 11/14 
scaffolds) whereas no bone deposition was observed 
with Ad-MSC (0/7 donors and 0/22 scaffolds) 8 weeks 
after subcutaneous implantation. The Ad-MSC results 
were moderately improved (1/3 donors and 2/6 scaf-
folds) by prolonging the observation period to 12 
weeks[42]. In Reinisch et al.[47], similarly, after subcu-
taneous implantation in mice, Ad-MSC seeded onto 
Matrigel™ were not able to induce bone formation 
contrarily to BM-MSC. This study is interesting be-
cause the superiority of BM-MSC over Ad-MSC was 
demonstrated using non-bioactive scaffold. Similar 
results were reported in rats (r) where the bone vo-
lume measured by µ-Computed Tomography (µCT) 
within the pores of scaffold was over 100 fold higher 
with rBM-MSC (6.85mm³ ± 1.89) than with rAd-MSC 
(0.05 mm³ ± 0.05) 6 weeks after implantation; this 
was further confirmed by histology[54].  
The Ad-MSC literature however shows that a pre- 
induction or a pre-differentiation step would be req-
uired for Ad-MSC to promote bone formation[87–90]. 
This would therefore suggest a lower intrinsic bone 
forming capacity of Ad-MSC compared to BM-MSC.   
This is supported by Brocher et al. and Hattori et al. 
who showed that pre-induction increases the rate of 
ectopic bone formation by Ad-MSC to the levels of 
non-induced and induced BM-MSC[42,52], but not by 
Reinisch et al. who confirmed the superiority of BM- 
MSC over Ad-MSC even under an induction protocol 
(β-TCP/HA, osteogenic stimulation and PTH injec-
tion)[47].  
However using µ-CT, pre-differentiated BM-MSC 
have been shown to display higher bone deposition 
onto the scaffolds (9.1 mm³ ± 1.1) than pre-differen-
tiated Ad-MSC (1.3 mm³ ± 0.1)[50]. This was also 
shown by Brocher et al. with 7% and 3% of bone de-
position for BM-MSC and Ad-MSC respectively, al-
though here the difference did not reach statistical 
significance. Interestingly too, this last study also 
demonstrated that pre-induction of BM-MSC is suffi-
cient for new bone formation without scaffold (3/3 
donors and 6/6 scaffolds) whereas Ad-MSC (0/5 do-
nors and 0/10) still require the osteoconductive mi-
croenvironment provided by the scaffold[42].   
In summary, BM-MSC have higher intrinsic bone 
formation capacity than Ad-MSC. Under pre-induc-
tion, the conclusion is more controversial but the re-
sults suggest that ectopic bone formation capacity of 
BM-MSC is quantitatively better than that of Ad-MSC 
and does not require osteoconductive scaffold.  
5.2 Bone Repair Capacity of BM-MSC and 
Ad-MSC  
From the large body of literature investigating the 
bone repair potential of BM-MSC and Ad-MSC on 
calvarial and long bones defects, direct comparisons 
between BM-MSC and Ad-MSC have been performed 
in only 6 articles: 3 (only 1 with human MSC) in crit-
ical size calvarial defect and 3 (only 1 with human 
MSC)  in critical size long bone defect.  
In rat critical size calvarial defect model, Wen et al. 
showed using X-Ray and histomorphometry that hu-
man BM-MSC and Ad-MSC have similar bone heal-
ing rate 8 weeks after implantation[53]. Autologous 
transplantation of BM-MSC and Ad-MSC in rabbit 
and pig calvarial model supports these observations. 
Indeed, mineralization rate and new bone formation 
volume determined by µ-CT were not significantly 
different between the two sources of MSC 12 weeks 
after implantation[55,57]. Nonetheless, more adipose 
tissue was observed in bone defect areas with Ad-MSC 
than BM-MSC indicating that Ad-MSC undergo adi-
pogenic differentiation even in a bone healing envi-
ronment.  
In critical size long bone defect, whereas one study 
in dogs showed comparable healing rate between ca-
nine BM- and Ad-MSC[56], two studies demonstrated 
that BM-MSC display higher bone healing capacity 
than Ad-MSC[51,58]. In rat femoral critical defect, new 
bone volume fraction values (BV/TV) quantified by 
µ-CT were significantly higher in human BM-MSC 
compared to human Ad-MSC 12 weeks after implanta-
tion, but the difference was lost with pre-induction[51]. 
Similarly, in a model of a critical size defect of sheep 
tibia, radiographic evaluations — confirmed histolog-
ically — revealed higher levels of newly formed bone 
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in ovine BM-MSC than in ovine Ad-MSC[58].  
Taken together, these 6 studies suggest that the 
bone repair potential of BM-MSC and Ad-MSC is site 
dependent. Whereas similar bone repair was observed 
in calvarial defect model, BM-MSC show better bone 
repair potential in the long bone defect model. A key 
element that might explain this difference is the type 
of ossification occurring during bone repair. Whereas 
flat bones such as calvaria undergo intramembranous 
ossification, long bones are repaired through endo-
chondral ossification. During long bone fracture repair, 
endochondral ossification occurs following four over-
lapping phases. After injury, disruption of vessels 
leads to hematoma formation followed by an intense 
angiogenesis and the formation of a soft callus. This 
angiogenesis is critical to the formation of the callus 
and therefore for bone healing and VEGF is a key 
player in this process (for review[91,92]). During bone 
fracture repair, VEGF is highly expressed and secreted 
by osteoblasts. Literature has showed that BM-MSC 
express more VEGF than Ad-MSC (see BM- and Ad- 
MSC gene signature section). BM-MSC could there-
fore promote better angiogenesis than Ad-MSC which 
may explain the higher osteogenic potential of BM- 
MSC in long bone defect compared to Ad-MSC. 
In summary, the in vivo data reported here support 
that BM-MSC display inherent bone formation capac-
ity superior to that of Ad-MSC. Indeed, the studies 
discussed in this review showed that BM-MSC have a 
higher bone formation capacity in non-induced as well 
as in induced conditions. Further studies have shown 
that Ad-MSC require pre-induction to promote bone 
formation. Yet, even with pre-induction, Ad-MSC fall 
short of BM-MSC quantitatively in terms of amount 
of newly formed bone. This inherent superior bone 
formation capacity of BM-MSC is further confirmed 
by the results from long bone defect studies. However, 
as BM-MSC and Ad-MSC have similar osteogenic 
potential in the calvarial critical size defect, one hypo-
thesis is that Ad-MSC osteogenic potential could de-
pend on the bone healing environment that is delayed 
when an endochondral ossification step occurred.  
6. Discussion and Conclusion 
The interest of MSC for regenerative medicine and 
their use as therapeutics in clinical trials has consi-
derably increased over the last decade. This interest 
has been fed by the discovery of various sources of 
MSC, which has triggered their preclinical compari-
son. However, despite the large number of studies per-
formed and articles published, an analysis of the cur-
rent state of literature underlines a strong heterogene-
ity between studies, making the comparison difficult. 
In the present article, we reviewed, in the context of 
bone repair, the general characteristics and the osteo-
genic capacity of MSC from bone marrow and adipose 
tissue, which are the two main sources of MSC cur-
rently studied preclinically and clinically. In this re-
view, literature was screened for side-by-side compar-
ison of BM and Ad-MSC and only articles that com-
pared MSC from the same donors or from age-and/or 
gender matched donors were retained.  
With respect to yield and proliferation, the analysis 
of comparative data gives inconsistent results and the 
superiority of one source over the other could not be 
concluded (5 studies favoured Ad-MSC, 3 favoured 
BM-MSC and 2 supported equivalence). This could be 
explained by the fact that many factors other than do-
nors’ age or gender (e.g., harvesting site, isolation pro-
cedures, time of cell processing, culture medium and 
supplements, initial seeding density, passage numbers 
and so on) could affect the proliferation rate and cul-
ture yield of MSC.  
The analysis of comparative data yields only few 
differences in the immunophenotype of BM-MSC and 
Ad-MSC (such as for CD49d, CD106 and PODXL), 
both MSC populations displaying the general profile 
of surface antigen expression defined for MSC[19]. 
However, at the molecular level, gene expression pro-
filing revealed that BM and Ad-MSC have different 
genetic signatures suggesting a commitment toward 
the cell fate of their origin (i.e., osteo/chondroblastic 
for BM-MSC and adipocytic for Ad-MSC).  
All in vitro studies investigating the differentiation 
potentials of BM-MSC and Ad-MSC when directed 
toward osteogenic, chondrogenic and adipogenic li-
neages under appropriate culture conditions agree that 
both have the capacity to differentiate into the three 
lineages. However, while some studies report that BM- 
MSC have a greater osteogenic differentiation capaci-
ty and Ad-MSC a better adipogenic capacity, others 
claim that BM-MSC and Ad-MSC display similar os-
teogenic, chondrogenic and adipogenic differentiation 
potentials. Discrepancies may be explained by differ-
ence in cell culture conditions (e.g., cell culture me-
dium, cell passages, induction reagents). Finally, in vivo 
comparative studies support a greater osteogenic poten-
tial of BM-MSC both qualitatively and quantitatively.  
In view of the results of this critical literature re-
view, the development of standardized protocols and 
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methods, the establishment of additional cell specifi-
cations and the application of rigorous quality controls 
are required to ensure reliable and consistent results in 
preclinical studies involving MSC.  
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